Catal­ent de­lays quar­ter­ly call as stock takes an­oth­er dive

Catal­ent said it is de­lay­ing its fi­nan­cial re­sults for the quar­ter, and it now ex­pects to cut $400 mil­lion in net rev­enue guid­ance for the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA